TATA-box binding protein associated factor 13 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored TAF13P2 profile across patient tissues and cancer cell-line models. TAF13P2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, TAF13P2 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, TAF13P2 RNA expression shows 9,264 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight OV, PAAD, and LAML as cancer lineages where TAF13P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF13P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF13P2 survival associations across molecular data types. TAF13P2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF13P2 RNA expression–survival associations across cancer types. High TAF13P2 expression shows unfavorable associations in OV, SKCM, DLBC, PRAD and PCPG, but favorable associations in THCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for TAF13P2 RNA expression.
This table summarizes TAF13P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for TAF13P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF13P2 shows lower tumor expression in PAAD and LUAD and higher tumor expression in BLCA and KICH. The PAAD box plot shows higher TAF13P2 RNA expression in normal versus tumor tissue (log2 FC = −0.425, t-test p = .006).
This table shows molecular features associated with TAF13P2 in patient tissues and cancer cell lines. In patient samples, TAF13P2 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
